Neurotoxicity of isolated limb perfusion with tumor necrosis factor

Journal of the Neurological Sciences

Volumn 158, Issue 1, 1998, Pages 1-4

  Drory, Vivian E ^a   Lev, Dina ^a   Groozman, Galina B ^a   Gutmann, Mordechai ^a   Klausner, Joseph M ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Hyperthermic isolated limb perfusion; Neuropathy; Neurotoxicity; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; ELECTROMYOGRAPHY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMB PERFUSION; MALE; MELANOMA; NERVE POTENTIAL; NEUROTOXICITY; PRIORITY JOURNAL; SARCOMA; SENSORY NEUROPATHY; SYMPATHETIC TONE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ARM; AUTONOMIC NERVOUS SYSTEM DISEASES; BIOLOGICAL RESPONSE MODIFIERS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; ELECTROMYOGRAPHY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEURAL CONDUCTION; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS; REFLEX, ABNORMAL; SARCOMA, KAPOSI; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032507984     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00098-7     Document Type: Article

References (16)

1. Drory V.E., Korczyn A.D. Sympathetic skin response: age effect. Neurology. 43:1993;1818-1820.
2. Edwards M.J., Soong S.J., Boddie A.W., Balch C.M., McBride C. Isolated limb perfusion for localized melanoma of the extremity: a matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch. Surg. 125:1990;317-321.
3. Forman A.D. Neurologic complications of cytokine therapy. Oncology. 8:1994;105-110.
4. Fraker D.L., Alexander H.R., Andrich M., Rosenberg S.A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 14:1996;479-489.
5. Haranaka K., Satomy N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer. 34:1984;263-267.
6. Hoekstra H.J., Schraffordt Koops H., de Vries L.G.E., van Weerden T.W., Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer. 72:1993;1224-1229.
7. Lienard D., Ewalenko P., Delmotte J.J., Renard N., Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10:1992;52-60.
8. Nagamatsu M., Schmelzer J.D., Zollman P.J., Smithson I.L., Nickander K.K., Low P.A. Ischemic reperfusion causes lipid peroxidation and fiber degeneration. Muscle Nerve. 19:1996;37-47.
9. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain. 118:1995;869-878.
10. Said G., Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res. Immunol. 143:1992;589-599.
11. Schraffordt-Koops H., Eggermont A.M.M., Lienard D., Soni N., Williams T., Thomas J.M. Isolated limb perfusion (ILP) with high dose TNFα, gamma-IFN and melphalan in patients with irresectable soft tissue sarcomas. A highly effective limb saving procedure. Eur. J. Cancer. 29A(Suppl. 16):1993;1017-1021.
12. Sharief M.K., McLean B., Thompson E.J. Elevated serum levels of tumor necrosis factor α in Guillain-Barré syndrome. Ann. Neurol. 33:1993;591-596.
13. Sorkin P., Abu-Abid S., Lev D.et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow-rate adjustment. Arch. Surg. 130:1995;1079-1084.
14. Tracey K.J., Beutler B., Lowry S.F.et al. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470-474.
15. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 102:1991;230-234.
16. Vrouenraets B.C., Keus R.B., Nieweg O.E., Kroon B.B. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors. J. Surg. Oncol. 65:1997;88-94.